BR112023002659A2 - Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor - Google Patents
Inibidores de cetona não hidratados de nav1.7 para o tratamento da dorInfo
- Publication number
- BR112023002659A2 BR112023002659A2 BR112023002659A BR112023002659A BR112023002659A2 BR 112023002659 A2 BR112023002659 A2 BR 112023002659A2 BR 112023002659 A BR112023002659 A BR 112023002659A BR 112023002659 A BR112023002659 A BR 112023002659A BR 112023002659 A2 BR112023002659 A2 BR 112023002659A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- compounds
- pain
- hydrated ketone
- ketone inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066012P | 2020-08-14 | 2020-08-14 | |
| PCT/US2021/046054 WO2022036297A1 (en) | 2020-08-14 | 2021-08-14 | Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002659A2 true BR112023002659A2 (pt) | 2023-05-02 |
Family
ID=77693595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002659A BR112023002659A2 (pt) | 2020-08-14 | 2021-08-14 | Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230339958A1 (https=) |
| EP (2) | EP4196482B1 (https=) |
| JP (1) | JP2023537632A (https=) |
| KR (1) | KR20230051252A (https=) |
| CN (1) | CN116368139A (https=) |
| AU (1) | AU2021326546A1 (https=) |
| BR (1) | BR112023002659A2 (https=) |
| CA (1) | CA3188924A1 (https=) |
| ES (1) | ES3061196T3 (https=) |
| IL (1) | IL300626A (https=) |
| MX (1) | MX2023001741A (https=) |
| WO (1) | WO2022036297A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110831945B (zh) | 2017-03-29 | 2023-08-08 | 赛特温治疗公司 | 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 |
| EP3860714B1 (en) | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| HRP20260068T1 (hr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CA2760946C (en) | 2009-05-07 | 2019-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
| JP6112867B2 (ja) * | 2010-02-10 | 2017-04-12 | ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ | サキシトキシン誘導体での触覚の喪失の処置 |
| ES2895155T3 (es) * | 2015-09-30 | 2022-02-17 | Siteone Therapeutics Inc | Saxitoxinas modificadas en 11,13 para el tratamiento del dolor |
| US11279706B2 (en) * | 2017-03-29 | 2022-03-22 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| EP3860714B1 (en) * | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
-
2021
- 2021-08-14 EP EP21766757.5A patent/EP4196482B1/en active Active
- 2021-08-14 EP EP25205463.0A patent/EP4647075A3/en active Pending
- 2021-08-14 IL IL300626A patent/IL300626A/en unknown
- 2021-08-14 WO PCT/US2021/046054 patent/WO2022036297A1/en not_active Ceased
- 2021-08-14 KR KR1020237008718A patent/KR20230051252A/ko active Pending
- 2021-08-14 BR BR112023002659A patent/BR112023002659A2/pt unknown
- 2021-08-14 US US18/041,523 patent/US20230339958A1/en active Pending
- 2021-08-14 JP JP2023511616A patent/JP2023537632A/ja active Pending
- 2021-08-14 CN CN202180063953.0A patent/CN116368139A/zh active Pending
- 2021-08-14 AU AU2021326546A patent/AU2021326546A1/en active Pending
- 2021-08-14 CA CA3188924A patent/CA3188924A1/en active Pending
- 2021-08-14 ES ES21766757T patent/ES3061196T3/es active Active
- 2021-08-14 MX MX2023001741A patent/MX2023001741A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001741A (es) | 2023-04-25 |
| KR20230051252A (ko) | 2023-04-17 |
| EP4196482B1 (en) | 2025-10-01 |
| CA3188924A1 (en) | 2022-02-17 |
| EP4647075A2 (en) | 2025-11-12 |
| EP4647075A3 (en) | 2026-01-14 |
| JP2023537632A (ja) | 2023-09-04 |
| AU2021326546A1 (en) | 2023-04-13 |
| WO2022036297A1 (en) | 2022-02-17 |
| IL300626A (en) | 2023-04-01 |
| ES3061196T3 (en) | 2026-03-31 |
| CN116368139A (zh) | 2023-06-30 |
| EP4196482A1 (en) | 2023-06-21 |
| US20230339958A1 (en) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023002659A2 (pt) | Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| JOP20230318A1 (ar) | مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1 | |
| BR112023018785A2 (pt) | Composto cíclico fundido com pirimidina, método de preparação do mesmo e uso do mesmo | |
| BR112022020841A2 (pt) | Inibidores de kras tricíclicos fundidos | |
| BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
| AU2018243463A8 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| BRPI0607897A2 (pt) | compostos oxindol e sua utilização como agentes terapêuticos | |
| BRPI0608402B8 (pt) | compostos de flavonóide e composições compreendendo os mesmos | |
| BRPI0720588B8 (pt) | derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase | |
| JOP20240235A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| BR0312924A (pt) | Biciclo-pirazóis ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos | |
| BR112022006018A2 (pt) | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| BR112023002089A2 (pt) | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| NZ737536A (en) | Substituted benzamides and methods of use thereof | |
| JOP20240238A1 (ar) | مثبطات أميد حلقة غير متجانسة ثنائية الحلقات لـ NaV1.8 لعلاج الألم | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112021017820A2 (pt) | Composições e métodos para modulação da atividade de complemento | |
| BR112022022452A2 (pt) | Inibidores de il4i1 e métodos de uso | |
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| MX377032B (es) | Compuestos de dihidroquinolinsulfonamida de alquilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |